Back to news

Bristol Myers Squibb gains as investors focus on fresh oncology data plans and recent Phase 3 pipeline wins

Investivoq PriceTracker

Bristol Myers Squibb (BMY) is up 4.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed optimism around Bristol Myers Squibb’s pipeline after the company highlighted a broad set of oncology disclosures for ESMO 2026, including late-breaking data from key programs. Shares also may still be benefiting from positive Phase 3 readouts announced earlier in October, which helped reinforce the view that several pipeline assets could support future growth.

Details:

  • On October 19, the company said it will present 12 oral presentations and nearly 60 disclosures at ESMO 2026, including late-breaking Phase 3 disclosures for izalontamab brengitecan in lung cancer and breast cancer.
  • On October 12, Bristol Myers Squibb said its Phase 3 ALOFT-IPF trial met its primary endpoint, with admilparant showing a statistically significant benefit on lung function versus placebo and a favorable safety profile.
  • Also on October 12, the company announced positive topline interim Phase 3 ACTION-1 results for RYZ101 in gastroenteropancreatic neuroendocrine tumors, giving investors two meaningful late-stage pipeline updates in one day.
  • Bristol Myers Squibb is scheduled to report third-quarter 2026 results on October 29, which could be adding to buying interest as investors position for further pipeline and business updates.

    • Sources:

    Bristol Myers Squibb, Google Finance, Stock Analysis

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $BMY Insider Trading Activity

    BMY Insider Trades

    $BMY insiders have traded $BMY stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

    Here’s a breakdown of recent trading of $BMY stock by insiders over the last 6 months:

    • CRISTIAN MASSACESI (EVP,Chief Med Offr,Head of Dev) sold 6,249 shares for an estimated $403,497
    • PHIL M HOLZER (SVP and Controller) sold 500 shares for an estimated $33,750

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive BMY Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $BMY Hedge Fund Activity

    We have seen 1,155 institutional investors add shares of $BMY stock to their portfolio, and 1,148 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • JPMORGAN CHASE & CO added 71,713,442 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,132,128,528
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 67,595,177 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,894,834,098
    • PRICE T ROWE ASSOCIATES INC /MD/ added 21,457,405 shares (+209.3%) to their portfolio in Q2 2026, for an estimated $1,236,375,676
    • BLACKROCK, INC. added 8,702,106 shares (+5.1%) to their portfolio in Q2 2026, for an estimated $501,415,347
    • PACER ADVISORS, INC. added 7,995,711 shares (+inf%) to their portfolio in Q2 2026, for an estimated $460,712,867
    • CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 6,479,804 shares (+10.6%) to their portfolio in Q2 2026, for an estimated $373,366,306
    • NORDEA INVESTMENT MANAGEMENT AB added 6,019,226 shares (+296.1%) to their portfolio in Q2 2026, for an estimated $346,827,802

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $BMY Government Contracts

    We have seen $11,795,749 of award payments to $BMY over the last year.

    Here are some of the awards which we have have seen pay out the most over the last year:

    • REVLIMID, POMALYST, CAMZYOS SPECIALTY PHARMACEUTICALS: $848,445
    • ABECMA FOR CAR-T: $378,650

    To track government contracts to publicy traded companies, check out Investivoq's government contracts dashboard. You can access data on government contracts through the Investivoq API government contracts endpoint.

    $BMY Congressional Stock Trading

    Members of Congress have traded $BMY stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

    Here’s a breakdown of recent trading of $BMY stock by members of Congress over the last 6 months:

    • REPRESENTATIVE MIKE KELLY sold up to $50,000 on 05/07.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.